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Summary.-In a microcytotoxicity assay the lymphocytes from cancer patients
were tested on autologous and allogeneic tumour cells in vitro. In patients with a
variety of tumours, extensive washing of the lymphocytes from those cases with
advanced disease was found to greatly enhance their specific cytotoxic effects. This
specificity was restricted to autologous tumour cells and allogeneic cells of similar
histological origin. This cross-reacting cytotoxicity was not, however, universal,
especially in cases of malignant melanoma. The cytotoxicity evoked by washing
was abolished by the addition of the patient's serum. This serum effect showed a
similar specificity to that found for lymphocyte cytolysis. The effect of washing,
and the specific inhibitory effect ofserum, was not detectable in earlycases ofprimary
malignant melanoma. The serum component responsible for inhibiting lymphocyte
cytotoxicity had no detectable affinity for the target cells and appears to act on the
lymphocyte surface, implying that tumour antigen may well be implicated.
THE peripheral blood lymphocytes
from patients with a variety of malignant
diseases are apparently capable of killing
tumour cells in tissue culture (Hellstrom
et al., 1971). The specificity of this
cytotoxic effect is restricted to tumours
of similar tissue of origin. Whether such
specificity is directed against tumour-
associated neo-antigens, or antigens de-
rived from the tissue of origin of the
tumour, remains unresolved. There are
also reports that the serum from these
patients inhibits the cytotoxic effects
of the lymphocytes, showing similar
specificity in its blocking effect. Initially,
this was ascribed to the presence of
" blocking antibody " which could coat
the tumour cells and thereby protect
them from the action ofcytotoxic lympho-
cytes. In this paper the word " blocking"
will not be employed as it has already
been so widely used in connection with
the effects of antibody. With the dis-
covery ofcarcinoembryonic antigen (CEA)
by Gold and Freedman (1965), it became
apparent that constituent macromolecules
from the surface of tumour cells can
appear in the serum. Evidence has
since accumulated in experimental animals
which suggests that immunogenic tumour-
associated antigens may similarly escape
into the extracellular fluid and serum and
that such serum antigens, possibly com-
plexed with antibody, can interfere with
cell-mediated responses in vivo (Sjogren
et al., 1971; Thomson and Alexander,
unpublished observations). Wehavethere-
fore considered the hypothesis that the
inhibitory component of the serum of
cancer patients may be circulating antigen
(possibly complexed with antibody) and
that the antigenic moiety interferes with
the anti-tumour action of the lympho-
cytes. In a study of lymphocyte cyto-
toxicity on freshly cultured autologous
melanoma cells, our results (Currie,
Lejeune and Fairley, 1971) were at
variance with those of Hellstrom et at.
(1971). Firstly, the incidence of cytotoxic
lymphocytes was substantially lower inG. A. CURRIE AND CONNIE BASHAM
our series and showed a correlation with
tumour burden, i.e., those patients with
cytotoxic lymphocytes had minimal
disease. Secondly, we were unable
to inhibit the cytotoxic properties of
the lymphocytes of these patients by the
addition of autologous serum to the
cultures. There was, however, an essential
difference in technique, in that the method
for obtaining lymphocytes from blood
used by Hellstrom's group (1971) involved
much more extensive washing than that
used by us (Currie et al., 1971).
Coggin (1972, unpublishedobservation)
has recently shown that the lymphocytes
from hamsters bearing SV40 induced
tumours can be rendered cytotoxic to the
tumour cells by extensive washing. In
this communication we show that after
extensive washing, lymphocytes from
patients with advanced disease, previously
not cytotoxic, acquire powerful tumour-
specific cytotoxicity and that the serum
from these patients inhibits this newly
evoked cytotoxic effect. The serum
inhibitory factor appears to show an
affinity for the lymphocytes.
MATERIALS AND METHODS
Tumour cultures.-The short-term tissue
cultures were prepared as described in our
previous paper (Currie et al., 1971). Cultures
were obtained from patients with bladder
carcinoma, hypernephroma, malignant mela-
noma and fibrosarcoma. The cells were
seeded into microtest culture plates (Falcon
3034) at approximately 200 viable cells per
well. The medium used was RPM1 1640
containing 10% foetal bovine serum, the
cultures were gassed with 5% CO2 in air and
incubated at 370.
Lymphocyte separation and the effects of
washing.-A volume of 20 ml of peripheral
venous blood was taken from each patient
and defibrinated with sterile glass beads.
This blood was then incubated with 200 mg
of carbonyl iron powder for 20 min and then
the red cells sedimented by the addition of
6 ml of 1% methyl cellulose for a further
20 min. The lymphocyte-rich plasma was
removed and centrifuged and the cells
washed by the addition of 20 ml aliquots of
Medium 199 at room temperature. The
lymphocytes were used after the first wash
and after the sixth. They were then counted
in a haemacytometer and made up in RPM1
1640-10% foetal bovine serum to the
appropriate concentration. This concentra-
tion was determined by counting the number
of cells in the tumour microcultures under
phase contrast and the lymphocyte suspen-
sion then adjusted to give a final lymphocyte
to tumour ratio of 400: 1. Lymphocytes
from normal individuals were obtained and
treated in an identical manner.
Serum inhibitory effects.-To test for the
effects of serum on lymphocyte cytotoxicity
the serum under test was incorporated into
the lymphocyte suspension before inoculation
on to the tumour cells. The concentration
used in most experiments was 5% and as
a control for each experiment normal
allogeneic serum was added at a similar
concentration to an identical aliquot of
lymphocytes.
Cytotoxic assay.-Thelymphocyte suspens-
ions were added in volumes of 10 ,ul to the
tumour cell cultures24hoursafterthe cultures
were established. After incubation at 37°
without agitation for 48 hours, the plates
were gently inverted and incubated for a
further 2 hours, when the supernatant was
aspirated from each well and the cultures
very careftilly rinsed with Medium 199.
They were then immersed in methanol for
1 hour and stained with Giemsa. The
plates were examined and the number of
cells in each well counted at x 60 magnifica-
tion using a graticule eyepiece. For each
experimental procedure at least 10 replicate
wells were studied, i.e., 10 control wells,
10 with normal lymphocytes, 10 with test
lymphocytes, etc. Comparisons were made
only between groups of wells on the same
microplate, i.e., each plate had its own group
of at least 10 control wells. The mean
number of cells left in each well + one
standard deviation was calculated, and the
percentage cytotoxicity calculated thus:
Mean no. ofcells
in control wells
Mean no. of cells
Cytotoxicity in test wells x 100%
in control wells
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RESULTS
1. Effect of washing on lymphocyte cyto-
toxicity
The detailed results of remaining
cell numbers 1 S.D. are shown in tabular
form (Table I). In the majority of cases
the lymphocytes were not cytotoxic after
a single wash, thus confirming the results
of Currie et al. (1971). The occasional
case, e.g., BLA 28, a bladder carcinoma,
did have cytotoxic lymphocytes after
one wash only, as did Me 314 and Me 315,
both primary melanomata. However,
after extensive washing (6 times) the
previously non-cytotoxic cases all became
significantly cytotoxic. This cytotoxicity
was apparent in cases of malignant
melanoma, bladder carcinoma, one case
of hypernephroma and one fibrosarcoma
when tested on autologous tumour cells.
Normal allogeneic lymphocytes obtained
from healthy laboratory workers were not
usually cytotoxic either before or after
the multiple washing. However, in one
instance there was an increase in such
nonspecific kill. This was not abolished
by incubation with the patient's serum,
a procedure which readily abrogated the
cytotoxic effect of the patient's lympho-
cytes (see below), i.e., it is a totally
nonspecific cytotoxicity and is readily
distinguishable from the specific effect
induced by the patient's lymphocytes.
The increase in cytotoxicity induced
by washing may have been due to the
trauma of multiple centrifugation. The
improbability of such a hypothesis was
demonstrated by spinning the " one
wash" lymphocytes 6 times and re-
suspending them in the same supernatant
each time. This procedure had no
effect on cytotoxicity. The initial choice
of 6 washes was based on the experience
of Coggin in the hamster model (personal
communication). Subsequently, it was
shown that this choice was appropriate
for man. Fig. 1 demonstrates the effects
of 1, 3 and 6 washes of autologous and
normal allogeneic lymphocytes on their
cytotoxic effects on Me 312 cells (a
malignant melanoma). It can be seen
that there is a progressive increase in the
cytotoxic effect of the patient's lympho-
cytes on the target cells, but no effect
on the normal lymphocytes. was detect-
able. The newly evoked cytotoxic effect
was readily abrogated by the subsequent
addition of autologous serum. In one
case of bladder carcinoma lymphocytes
were available from the uninvolved drain-
ing regional nodes and these. were tested
for their cytotoxic effects on the auto-
logous tumour cells before and after
washing. The effects of autologous serum
on these lymph node cells was also tested.
These results are shown in Table I and
indicate that washing the lymph node
cells increases their cytotoxic effect and
that this cytotoxicity can be inhibited by
autologous serum.
The extensive washing required to
reveal cytotoxicity may be interpreted
in one of 2 ways. The component
responsible for inhibiting cytolysis may
either be very powerful and thus require
extensive washing to dilute out its effects,
or it may be bound to the lymphocyte
surface. These possibilities were explored
in one case of malignant melanoma
(Me 318). The patient's lymphocytes
were tested on autologous tumour cells
after 6 washes. When tested in control
serum they were powerfully cytotoxic.
The inhibitory activity of the autologous
serum was examined in dilutions starting
at 10% serum. It can be seen from
Table I and Fig. 2 that this inhibitory
activity diluted out at 2.5% serum.
This would suggest that the serum
inhibitor must have some degree of
affinity for the lymphocyte surface. The
fact that at high concentration (e.g.,
10%) the serum was not as effective as at
5% is intriguing but as yet unexplained.
2. Cross-reactivity of the lymphocyte cyto-
toxicity
In most instancesthepatients' lympho-
cytes were tested on autologous tumour
cells. However, attempts were made to
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TABLE I.-Cytotoxicity of Patients' Lymphocytes on Tumour cell Microcultures. The
Results are Expressed as Mean Number of Cells Remaining per Well + 1 S.D.
Diagnosis
H Hypernephroma
. Hypemephroma
. Normal donor
. Normal donor
. Bladder carcinoma
. Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
Bladder carcinoma
BdNormal
Normal
Fibrosarcoma
* Fibrosarcoma
* Fibrosarcoma
F Normal
* Normal
Malignant melanoma
*Malignant melanoma
Malignant melanoma
. Malignant melanoma
Malignant melanoma
. Malignant melanoma
. Normal
. Normal
. Normal
Malignant melanoma
. Before
. Autoimmunization
. Day 0
. Normal
. Normal
. Malignant melanoma
. 7 days after
. Autoimmunization
. Autoimmunization
. Autoimmunization
Target
cells
. HYP 19
. HYP 19
. HYP 19
. HYP 19
. HYP 19
.BLA26
.BLA26
. BLA26
.BLA26
.BLA24
.BLA24
. BLA24
. BLA24
.BLA24
.BLA24
. BLA24
.BLA24
.BLA24
.BLA24
.BLA24
.FS2
.FS2
.FS2
. FS2
. FS2
. FS2
* Me304
* Me304
* Me304
*Me304
* Me304
Me304
. Me 304
. Me 304
. Me 304
Me 304
. Me 307
. Me 307
. Me 307
. Me 307
. Me 307
. Me 307
. Me 307
. Me307
. Me 307
. Me 307
. Me 307
. Me 307
. Normal . Me 307
. Normal . Me 307
. Me 307
. Malignant melanoma . Me 312
(recurrent)
. Malignant melanoma . Me 312
(recurrent)
. Malignant melanoma . Me 312
(recurrent)
. Malignant melanoma . Me 312
(recurrent)
No. of
washes
6
6
6
6
1
6
6
1
6
1
6
1
6
1
6
1
6
1
6
6
1
6
1
6
6
1
6
6
1
6
6
1
1
6
6
1
6
1
6
6
6
6
1
6
1
3
6
6
Serum
added
Control
Autologous
Control
HYP 19
. Control
. Control
. Autologous
. Control
. Control
. Autologous
. Control
. Control
. Control
. Control
. Autologous
. Control
. Control
. Autologous
. Control
. Control
. Me 304
. Control
. Autologous
. Control
. Autologous
. Control
. Control
. Control
. Control
. Me 307 Day 0
. Me 307 Day 7
. Me 307 Day 0
+Day 7
. Control
. Control
Control
. Control
. Control
. Autologous
Target cells
left in well
8±1*3
33±4-4
59±3 5
61±2-6
66+3-6
16±3
11 5+3
25±4
27±5*5
16+4
15±8
31±6
14+5
37±3
9+5
56+5
25±8
55+6
56±5
58±6
138+15
7±5
163±15
153±9
71±28
171±8
141±11
94±17 5
198±12
102±11
109+22
209±11
187±10-5
135±2-
139±8
225+19
16±0*5
17±1-7
5±b17
14±1 8
21±2
18±0-5
18±0-6
101±10
16+10
108±13
15±4
104+26
177±1]
175±15
227±15
83±18
50+5
26±8
73±11
Lymphocytes
HYP 19
HYP 19
Control
Control
Nil
BLA 26
Lymph node
cells
Lymph node
cells
Lymph node
cells
Nil
BLA 28
BLA 29
BLA 30
BLA 31
Control
Nil
FS 2
FS 2
FS 2
Control
Control
Nil
Me 304
Me 304
Me 304
Me 305
Me 305
Me 305
Control
Control
Control
Nil
Me 307 Day 0
Me 307
Me 307
Me 307
Nil
Control
Control
Me 307 Day 7
Me 307
Me 307
Me 307
Me 307
Control
Control
Nil
Me 312
Me 312
Me 312
Me 312
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Diagnosis
Malignant melanoma
(metastatic)
Malignant melanoma
(metastatic)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Normal
Normal
Normal
Malignant melanoma
(metastatic)
Malignant melanoma
(metastatic)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Malignant melanoma
(primary)
Normal
Malignant melanoma
Malignant melanoma
Malignant melanoma
Malignant melanoma
Malignant melanoma
Malignant melanoma
Normal
Normal
Malignant melanoma
(nasal)
Malignant melanoma
(nasal)
Bladder carcinoma
Bladder carcinoma
Ethmoid carcinoma
(transitional cell)
Ethmoid carcinoma
(transitional cell)
Normal
Normal
Malignant melanoma
(disseminated)
Malignant melanoma
(disseminated)
Malignant melanoma
(disseminated)
Malignant melanoma
(disseminated)
Malignant melanoma
(disseminated)
Malignant melanoma
(disseminated)
Hypernephroma
Hypernephroma
Target
cells
. Me 312
Me 312
Me 312
. Me 312
. Me 312
. Me 312
. Me 312
. Me 312
. Me 312
. Me 312
. Me 313
. Me 313
. Me 313
. Me 313
. Me 313
. Me 313
. Me 313
Me 313
. Me 314
. Me 314
. Me 314
. Me 314
. Me 314
. Me 314
Me 314
. Me 314
. Me 314
Me 311
. Me 311
Me 311
Me 311
. Me 311
Me 311
Me 311
Me 311
. Me 311
. Me 318
* Me 318
. Me 318
. Me 318
. Me 318
. Me 318
. Me 318
. Me 318
No. of
washes
6
6
6
6
6
6
1
3
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Serum
added
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Control
. Control
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
. Autologous
. Control
Me 311
. Control
.10%
autologous
.5%
autologous
. 2-5%
autologous
. 1.25%
autologous
. HYP 21
. Control
HYP 21
Target cells
left in well
16+3
66±12
11+3
14±3
28+3
19+7
102±7
103±7
87±17
103±11
149±19
196+7
76±16
62±15
202±7
217±15
230±18
232±14
17±4
50±6
9±4
13±4
63±13
69±13
98±8
99±12
122±7
28±4
55±12
46±11
41±8
56±5
60±6
69±8
67±7
64±7
43±4
124±13
172+18
128±11
42±7
46±4
169±11
167±16
Lymphocytes
Me 313
Me 313
Me 314
Me 314
Me 315
Me 315
Control
Control
Control
Nil
Me 313
Me 313
Me 314
Me 314
Me 315
Me 315
Control
Nil
Me 313
Me 313
Me 314
Me 314
Me 315
Me 315
Control
Control
Nil
Me 311
Me 311
BLA 50
BLA 50
Eth 1
Eth 1
Control
Control
Nil
Me 318
Me 318
Me 318
Me 318
Me 318
Me 318
HYP 21
HYP 21
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x
0
0
C-
* NORMAL ALLOGENEIC LYMPHOCYTES
O AUTOLOGOUS LYMPHOCYTES
I
1 2 3 4 5 6 6 washes
No. OF WASHES Me 312
serum
FIG. 1. Effect of increasing number of washes on cytotoxicity of lymphocytes from a patient with
extensive malignant melanoma tested on his autologous tumour cells (Me 312). The cytotoxic
effect increases with washing and this increase is abolished by the addition of autologous serum.
examine the cross-reactivity of lympho-
cyte cytolysis on tumours of similar and
dissimilar histological diagnosis. Fig. 3
shows the effect of lymphocytes from
4 cases of bladder carcinoma (and one
normal) tested on an allogeneic bladder
tumour culture after one and 6 washes.
It can be seen that there is a cross reaction
of lymphocyte kill on bladder tumour
cells. The difference in cytotoxicity
between minimally washed, and 6 washed,
lymphocytes from each case seems to
reflect the serum inhibitory activity.
A similar cross-reactivity can be seen
in cases ofmalignant melanoma (Table II).
These cases also provided an opportunity
to compare the cytotoxic effect of the
patients' lymphocytes on both autologous
and allogeneic melanoma cells. The
results indicate that cross reactions in
cytotoxicity do occur but also show
that such cross reactivity is not universal.
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iUU
CYTOTOXICITY
50
n
10 5 2.5 1.25 0
°/o AUTOLOGOUS SERUM ADDED
FIG. 2.-Effect of decreasing concentrations of autologous serum on cytotoxicity of well washed
lymphocytes on autologous melanoma cells (Case No. Me 318). The inhibitory effect dilutes out at
between 1-25 and 2-5% serum.
For instance, thelymphocytesfrompatient
Me 315 were highly cytotoxic on Me 312
cells, but without cytotoxic effect on
Me 313 cells, whilst causing only feeble
cytolysis on Me 314. Furthermore, auto-
logous cytotoxicity in case Me 313 was
less pronounced than that obtained on
allogeneic melanoma cells. There was
no evidence of cytotoxicity of these
patients' lymphocytes on human embryo
lung fibroblasts. The cross reacting
cytotoxicity of the patients' lymphocytes
was however restricted to tumours of
similar tissue of origin, i.e., lymphocytes
from a patient with bladder carcinoma
would not kill either melanoma or fibro-
sarcoma cells. Furthermore, the speci-
ficity of lymphocytes was not decreased
by multiple washing, i.e., nonspecific
cytotoxicity was not induced.
3. Inhibitory effect of sera
The increase in specific cytotoxicity of
the patients' lymphocytes with multiple
washing would imply that some form of
inhibitory factor was being removed.
Furthermore, the number of washes re-
required to reveal the cytotoxic effects
would perhaps suggest that the inhibitory
factor is bound to the lymphocyte surface.
The fact that this inhibitor is a serum
component was readily demonstrated by
adding autologous serum to the washed
lymphocytes. Table I shows that the
newly acquired cytotoxicity induced by
washing of the patients' lymphocytes
was abolished by the addition of auto-
logous serum to the reaction mixture.
In the few cases where washing increased
the nonspecific cytotoxicity of normal
allogeneic lymphocytes, the inhibitory
TABLE II.-Cross-reactivity of the Cytotoxic Effects of Lymphocytes from Patients with
Malignant Melanoma on Autologous and Allogeneic Melanoma Cells. The Figures
represent Mean Cytotoxicity as a Percentage. CS with Control Serum. AS =
with Autologous Serum
Lymphocytes
t A
Target cells
Me 312
Me 313
Me 314
Control
CS AS
1 3
1 0
20 19
Me 312
CS AS
75 29
NT NT
NT NT
Me 313
CS AS
83 36
36 16
86 59
Me 314
CS AS
89 86
67 73
93 89
Me 315
CS AS
74 82
13 7
48 43
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x
0
I-
0
0
{ 1 WASH
{ 6 WASH
NORMAL BLA BLA BLA BLA
ALLOGENEIC 28 29 30 31
CONTROL
FIG. 3.-Cytotoxicity of lymphocytes from 4 cases of bladder carcinoma and one normal control on
allogeneic bladder carcinoma cells before and after extensive washing.
sera had no such effect. Furthermore,
normal human serum had no effect on the
patients' lymphocytes after washing. This
serum inhibition appeared to possess
specificity for the histological tumour
type, i.e., serum from a patient with
malignant melanoma would only inhibit
lymphocytes from other melanoma
patients. Furthermore, an active inhibi-
tor serum from a patient with bladder
carcinomahadnoeffectonthelymphocytes
from patients with malignant melanoma.
There were a few cases in which this
serum inhibitory activity was undetect-
able. It is of interest to note that these
were cases with a minimal tumour burden,
e.g., Me 314 and Me 315, small primary
malignant melanomata; those cases with
an active serum inhibitory effect were all
cases of advanced disease.
4. Effect of auto-immunization with irradi-
ated cells
In one case of malignant melanoma
(Me 307) with multiple subcutaneous de-
posits over the arms and trunk, it was
decided to test his lymphocytes and serum
before and after auto-immunization with
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his own tumour cells. Several of the
subcutaneous lesions were removed sur-
gically and a mechanical cell suspension
obtained from them. 5 x 108 cells were
irradiated in a 60Co source to a total dose
of 12-5 krad and then injected sub-
cutaneously in multiple sites. The studies
of his lymphocyte cytotoxicity are shown
in Table I. The lymphocytes were tested
on cultures ofautologous tumour cells.
On Day 0 his lymphocytes were not
cytotoxic until washed 6 times, and his
serum was inhibitory. On the seventh
day after immunization his lymphocytes
were powerfully cytotoxic after only one
wash, and the Day 7 serum was incapable
of preventing this cytotoxicity. It was,
however, inhibited by the serum saved
from Day 0. In other words the auto-
immunization procedure had abolished
the serum inhibitory activity although the
lymphocytes were still amenable to inhi-
bition by an appropriate serum.
5. Affinity of the serum inhibitory factor
In the case auto-immunized with his
own cells the effect of Day 0 and Day 7
sera on lymphocyte cytotoxicity was
examined in 2 ways. Firstly, the sera
were incorporated at 5% into the lympho-
cyte suspensions as described above.
They were also tested by pre-incubation
of the target cells in 50% serum for one
hour at 37°. After washing the wells
with culture medium the lymphocytes
were then added and their cytotoxicity
measured. The results are shown in
Table I. The Day 0 serum had a powerful
inhibitory effect on cytotoxicity when
incorporated into the lymphocyte sus-
pension but was without effect when
pre-incubated with the target cells. The
Day 7 serum, however, had no inhibitory
effect when added to the lymphocytes
(at 5%) but when pre-incubated with the
target cells (at 5000) produced significant
inhibition of lymphocyte killing.
This would suggest that the serum
taken before auto-immunization possessed
an inhibitory factor with an apparent
affinity for the effector cells but with
no affinity for the target cells, i.e., it is
unlikely to be anti-tumour antibody but
is more likely to be circulating antigen.
The serum taken after immunization with
tumour cells had only a weak inhibiting
effect, detectable at high concentration
and with affinity for the target cells,
i.e., it would seem that the patient's
response to immunization was the develop-
ment of anti-tumour antibody which was
responsible for removing the serum inhibi-
tor, antigen.
DISCUSSION
Our earlier work on the cytotoxicity of
lymphocytes from patients with malignant
melanoma showed that only lymphocytes
from patients with minimaltumourburden
were cytotoxic to autologous tumour cells
(Currie et al., 1971). The present investi-
gation indicates that this was a somewhat
simplified view of the real situation.
The majority, perhaps all, of the patients
with tumours such as malignant mela-
noma, bladder carcinoma and hyper-
nephroma have peripheral blood lympho-
cytes capable ofkilling autologous tumour
cells in tissue culture. The cytotoxic
effects were, however, detectable only
after extensive washing of the lympho-
cytes and could be inhibited by the
addition of autologous serum but not by
normal allogeneic serum. This demon-
stration of specific serum inhibition of
lymphocyte function is in accord with
the findings of Hellstrom et al. (1971).
In cases with a minimal tumour burden
we were unable to detect the serum
inhibitory effect. The fact that in the
majority of cases with disseminated dis-
ease, lymphocyte cytotoxicity was
detectable only after multiple washing
would suggest that the inhibitory factor
was bound to the lymphocyte surface.
Since it could be readily washed off the
target cells, it is unlikely to be circulating
anti-tumour antibody. The abrogation
of lymphocyte cytotoxicity by circulating
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anti-tumour antibody has always been a
difficult phenomenon to accept as an
important in vivo mechanism. The exist-
ence of concomitant immunity in the
tumour bearing host has always argued
against it. However, the possibility that
antigen is responsible for the inhibition
of lymphocyte function, both local and
systemic, is not open to the same criti-
cisms. The correlation of the inhibitory
activity of serum with the extent of the
disease, and its apparent affinity for the
lymphocyte, would also suggest that
circulating tumour antigen is a more
likely candidate. The fact that auto-
immunization with irradiated tumour
cells abolished the serum inhibitory ac-
tivity in the case of malignant melanoma
studied, would perhaps indicate that the
serum inhibitor (? circulating tumour cell
antigen) was cleared from the circulation
by antibody (Ikonopisov et al., 1970), thus
exposing the cytotoxic effect of the
lymphocytes.
The degree ofspecificity ofthe lympho-
cyte cytotoxicity demonstrated in this
work is complex. Lymphocytes from the
cancer patients did not kill human
embryo lung fibroblasts. They did, how-
ever, kill the autologous tumour cells
and, in many cases, allogeneic tumour
cells of similar histological origin. This
latter finding would suggest that tumours
derived from the same tissue possess
similar cross reacting antigens. The
extent of such cross reactions is unclear.
In this study, especially of cases of
melanoma, there was only partial cross
reaction between cases. There may also
have been a difference in the degree of
antigenic expression by cells from different
patients. There was no convincing evi-
dence that autologous cytotoxicity was
consistently greater than that obtained
with allogeneic targetcells. Thevariations
in susceptibility to cytotoxic lymphocytes
between individual tumours of similar
diagnosis may reflect either a quantitative
or qualitative difference in their antigenic
expression. There is little tangible evi-
dence from this type of study that the
target cells possess tumour-associated
neo-antigens. The cross reactivity on
tumours derived from the same tissue or
organ may well reflect autoimmune re-
actions to organ- or tissue- specific
antigens expressed on the surface of the
tumour cells. Autoantibodies to many
normal tissue components are known to
be present in the sera of cancer patients
(Whitehouse and Holborow, 1971) and
it is conceivable that cell-mediated re-
actions to organ and tissue specific
antigens may masquerade as tumour-
specific reactions. A possible explanation
for the cross reactivity is that malignant
transformation is associated with exposure
of an antigen on the cell surface, which is
normally present but shielded by some
material and therefore not " expressed "
oIn the normal tissue. The malignant
change would, therefore, not consist of
the synthesis of a neo-antigen but a
change which allows an existing macro-
molecule to be expressed and detected by
the host's immunological apparatus.
The demonstration of serum factors
capable of specifically inhibiting the
in vitro cytotoxic propertiesofthepatient's
lymphocytes raises the question of the
role, if any, of such factors in vivo. If,
as we have postulated, they are solubilized
tumour antigens in one form or another,
then the constant release ofsuch potential
inhibitors of cell-mediated immunity from
the tumour cell surface could be held to
play a vital role in the natural history of
immune reactions to tumours. Alexander
and his colleagues (1967) have shown that
the presence of a small limb tumour in the
rat effectively paralyses the regional
draining lymph nodes, inhibiting the
propagation of specific cell-mediated re-
sponses from the nodes. The most
convenient explanation of such a pheno-
menon would seem to be local inhibition
of the node lymphoid cells by their
persistent exposure to low concentrations
of tumour antigen. As the tumour
progresses and the local node is over-
whelmed, then antigen may well reach
the circulation and its concentration there
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increase with tumour growth. In this
way central inhibition of lymphocyte
function by tumour antigens could be
held to account for both local and systemic
abrogation of immune responses.
In the design of any immunological
treatment of human tumours, the effect
of any potential therapy on serum inhi-
bitory activity will obviously have to be
borne in mind. We have described here
a single case in which auto-immunization
with tumour cells abolished the patient's
serum inhibitory activity. In our previous
series of patients treated in this way,
5 out of l2 cases " developed " cytotoxic
lymphocytes following immunization
(Currie et al., 1971). In the light of the
present experiments, it would seem that
these cases may well represent the dis-
appearance of serum inhibitors. Bansal
and Sj6gren (1971) have suggested that
the ability of an " immune " serum to
remove blocking activity from tumour
bearing serum may well correlate with its
in vivo anti-tumour effects. They treated
rats bearing polyoma tumours with these
so-called " de-blocking sera " and were
able to induce complete tumour re-
gression. The mechanism ofthisregression
was unclear. It is feasible that it was
merely the cytotoxic effect of the sera
on the target cells. However, should
this phenomenon prove to be due to the
" de-blocking " activity ofthe serum, then
this experiment would indicate that the
serum inhibitory activity plays an impor-
tant, even crucial, role in inhibiting
tumour rejection.
Further investigation of the nature
and activity of these tumour-associated
serum factors and their correlation with
clinical status will help to elucidate their
role in vivo. Should they prove to be
important specific in vivo moderators of
cell-mediated immunity in cancer patients,
then they provide a distinct hope for
immunotherapeutic techniques. Such
serum factors are readily detectable, even
quantitatible entities, and the measure-
ment of changes in them would provide
a valuable means of monitoring any form
of immunological treatment. Quanti-
tation of serum inhibitory factors may
also be of value in assessing tumour
burden. If they reflect the extent of the
disease, then they may be useful both for
measuring the effects oftreatment and for
early detection of recurrence.
This communication also draws atten-
tion to a potential source of error in any
studies of lymphocyte cytotoxicity of
tumour cells in vitro. The method of
preparation of the lymphocytes and the
degree of washing they receive appears
to be a crucial variable which must be
borne in mind when drawing any con-
clusions about cytotoxicity and the effects
of serum components.
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